by Raynovich Rod | Aug 14, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Small Caps are Growth and innovation Plays For Your Portfolio Many pundits and analysts are still calling this second half 20% move as a ” bear market rally” so we are in a fight the FED move? The XBI remains our key indicator for small cap biotechs, It is...
by Raynovich Rod | Aug 6, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-3 on JY 11 We will offer 3 updates in coming days: Healthcare Model, Large Cap Biopharma and Small/mid caps. Here are some notes on today’s market action: Momentum appears to be ebbing on profit taking.A bit of sector rotation into energy today with XLE...
by Raynovich Rod | Jul 26, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
On Vacation thru August 5 JY 26 2P EDT…Healthcare portfolios look good. :Large cap biopharmas green. IBB up 0.9% at $123.75.
by Raynovich Rod | Jun 27, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-3 July 5 11a EDT Rally in speculative biotech stocks with XBI up1.85% to $77 handle. Early movers: AGEN, CRSP, CYRX, DNA, QDEL, ROIV, VCYT all on our focus list. Added to Moderna (MRNA) at $153. Market indices in red on recession fears with S%P 500 down 1.9%...
by Raynovich Rod | Jun 21, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 June 22…Market ends trading day flattish with usual choppiness focused on macro after Powell speaks. Recession fears dominate with energy stocks down again. Bright spot is healthcare sector led by large caps with nibbling in beaten- up small caps. Like...
by Raynovich Rod | Jun 13, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 6/20 10:30p PDT…. Futures are up poised for a nice rally tomorrow. Last week even healthcare stocks hit new YTD lows with the XLV down 14.91% YTD now at $119.89. Even large cap biopharma stocks have sold off over the past month. ==== Update-1 FED raises...
by Raynovich Rod | May 30, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks, Macro
Update-4 June 8 Sideways market with trading opportunities in Small cap biotechs. With markets so choppy day to day and volatile within day it is hard to trade. But in my most recent trades I am more hopeful with this buying window. The bellwether remains XBI which...
by Raynovich Rod | May 15, 2022 | 2021 Rayno Biopharmaceuticals Portfolio
May 25 -Update-3 ..We will take this little rally after all the turmoil recently. Our Strategy has not changed since January which is to stay with large cap biopharma stocks . We would like to pick some winners among the smaller cap biotech and diagnostics stocks but...
by Raynovich Rod | May 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 …5/13 Many analysts see today’s sharp upside action as an oversold rally from 2022 lows.The highest risk stocks soared along with large cap tech stocks. NASDAQ was up 3.75%,S&P up 2.3%, DOW up 1.42%. To some extent this shifted action away...
by Raynovich Rod | Apr 28, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update -5 …5/6 A wild volatile week catalyzed by FED policy statements. We won’t go into the debate over FED communications about rate hikes and just say that rising rates are a headwind for equities and curb speculation. With higher rates small cap growth...
